Back to Pediatrics
Pediatricsv1.0Evidence-Based

Celecoxib (Celebrex) Pediatric Dosing

Weight-band celecoxib dosing for juvenile rheumatoid arthritis (oral).

Clinical Input Parameters

kg
Range: 2 — 150 kg
Clinical Assessment
Awaiting Parameters
dose mg
—mg
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Celecoxib (Celebrex) Pediatric Dosing is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within pediatrics.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

weight 10-25 kg -> 50 mg BID; weight >25 kg -> 100 mg BID

Clinical Pearls & Practice Notes

  • FDA-approved for JRA in children >= 2 years
  • 10-25 kg: 50 mg twice daily; >25 kg: 100 mg twice daily

Evidence & Literature Citations

  1. FDA Prescribing Information: Celebrex (celecoxib).

Score Interpretation Ranges

calculated0 – pts

Weight-based dose

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.